LYEL logo

Lyell Immunopharma, Inc.

LYEL
Healthcare|Biotechnology|US
$14.86
-0.14 (-0.93%)
DCF Value
$0.36
Tangible Book / Share
$7.89
Cash / Share
$7.25
Next Earnings Report
Mar 11, 2027
EPS est. -$1.98 · Revenue est. $2.8K
Financing Filings (last 12 months)
4
Shelf registrations / offering prospectuses — latest Jul 13, 2026 (S-3). Possible dilution.

Upcoming Data Readouts (3)

Jun 2028
Est. completion
P1P2Colorectal Cancer
LYL273 for Patients With Relapsed or Refractory mCRC
NCT05319314n=155
Dec 2028
Est. completion
P1P2Relapsed Non-Hodgkin Lymphoma
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
NCT05826535n=270
Dec 2029
Est. completion
P3Large B-cell Lymphoma
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
NCT07188558n=400

Recent Press Releases

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2026
Nov 4, 2026 · GlobeNewsWire
Lyell Immunopharma Announces $80 Million Private Placement to Advance Ronde-Cel Toward Planned BLA Submission
Nov 4, 2026 · GlobeNewsWire
Lyell Immunopharma to Present Positive Updated Ronde-Cel Data in More than 80 Patients at ASH 2026 from PiNACLE Pivotal Trial in 3L+ and from Phase 1/2 2L Cohort in Patients with Relapsed/Refractory Large B-Cell Lymphoma
Nov 4, 2026 · GlobeNewsWire
Lyell Immunopharma To Participate in November Investor Events
Nov 2, 2026 · GlobeNewsWire
Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference
Sep 14, 2026 · GlobeNewsWire
Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer
Sep 10, 2026 · GlobeNewsWire

SEC Filings (76)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 4, 202610-QQuarterly reportDocumentIndex
Nov 4, 20268-KMaterial eventDocumentIndex
Nov 4, 20268-KMaterial eventDocumentIndex
Sep 10, 20268-KMaterial eventDocumentIndex
Aug 14, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 6, 202610-QQuarterly reportDocumentIndex
Aug 6, 20268-KMaterial eventDocumentIndex
Jul 21, 2026EFFECTDocumentIndex
Jul 13, 2026S-3Shelf registrationDocumentIndex
Jun 18, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jun 15, 20268-KMaterial eventDocumentIndex
May 15, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 11, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 8, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 6, 202610-QQuarterly reportDocumentIndex
May 6, 20268-KMaterial eventDocumentIndex
Apr 24, 2026ARSAnnual report to holdersDocumentIndex
Apr 24, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 24, 2026DEF 14AProxy / shareholder voteDocumentIndex
Apr 21, 2026SC 13GPassive 5%+ stakeDocumentIndex
Apr 14, 2026EFFECTDocumentIndex
Apr 3, 2026S-3Shelf registrationDocumentIndex
Mar 12, 2026S-8Employee stock planDocumentIndex
Mar 12, 202610-KAnnual reportDocumentIndex
Mar 12, 20268-KMaterial eventDocumentIndex
Mar 9, 20268-KMaterial eventDocumentIndex
Dec 18, 2025424B5Offering prospectusDocumentIndex
Dec 15, 2025EFFECTDocumentIndex
Dec 8, 20258-KMaterial eventDocumentIndex
Dec 5, 2025S-3Shelf registrationDocumentIndex
Dec 5, 20258-KMaterial eventDocumentIndex
Nov 14, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Nov 14, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Nov 13, 2025SC 13GPassive 5%+ stakeDocumentIndex
Nov 12, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Nov 12, 202510-QQuarterly reportDocumentIndex
Nov 12, 20258-KMaterial eventDocumentIndex
Nov 10, 20258-KMaterial eventDocumentIndex
Nov 3, 20258-KMaterial eventDocumentIndex
Sep 16, 20258-KMaterial eventDocumentIndex